Authors
Latest:
Dr Billè on the Use of Minimally Invasive Surgery vs Stereotactic Radiotherapy in NSCLCAndrea Billè, MD, discusses findings from a propensity-matched comparison of minimally invasive surgery vs stereotactic ablative radiotherapy in patients with clinical stage I non–small cell lung cancer.
Latest:
Women in Oncology: Leukemia Therapies in Humans, for HumansJudith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..
Latest:
Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRCNilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.
Latest:
Dr Punekar on the Importance of Complete Biomarker Testing in Lung CancerSalman R. Punekar, MD, discusses the importance of complete biomarker testing and the landscape of biomarkers in lung cancer.
Latest:
Dr. Moyers on Real-World Data With Adjuvant Immunotherapy in MelanomaJustin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.
Latest:
The Future of Ovarian Cancer TreatmentOncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.
Latest:
Dr. Gupta on the Use of Platinum Plus Standard Neoadjuvant Chemotherapy in TNBCSudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer.
Latest:
Dr Ged on the Background of the ORCHID Trial in BAP1-Mutated Metastatic RCCYasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.
Latest:
Future Perspectives in EGFR+ NSCLCGlobal perspectives on the future management of EGFR+ non–small cell lung cancer given recent advances in the treatment paradigm.
Latest:
Dr. Hwang on First-line Treatment Options in HCCJimmy Hwang, MD, discusses currently available first-line treatment options in hepatocellular carcinoma, and areas of continued unmet need in this space.
Latest:
Dr. Barata on Patient-Reported Toxicities With Axi-Cel at 1-Year of Follow-UpAnna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.
Latest:
Future of R/R DLBCLA panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
Latest:
Neoadjuvant Immunotherapy in Mismatch Repair–Deficient, Early-Stage Colorectal Cancer: The Plot ThickensFor decades, resection of the primary tumor, either up front or after neoadjuvant therapy, has remained the standard of care for patients with early-stage (stage I-III) colorectal cancer. Recently, a plethora of data have been published that might change the current surgery-centered paradigm.
Latest:
Practical Advice on the Management of Tumor Lysis SyndromeClosing out his discussion on tumor lysis syndrome, Anthony Perissinotti, PharmD, BCOP, shares practical advice on its identification and management.
Latest:
Advancement in Treating Uncommon EGFR Mutations: Key TakeawaysDiscover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.
Latest:
A New Generation of Cytokine-Based Immunotherapy Takes ShapeNearly 40 years after the first cytokine-based therapy was approved for the treatment of patients with hairy cell leukemia, investigators are taking a fresh look at ways to leverage these signaling proteins to enhance immunotherapies and vaccines in other cancers.
Latest:
Find the Job That’s Right for YouThe American Society of Clinical Oncology projects significant shortages of practicing oncologists compared with patients with new cancer diagnoses and existing cancer by 2025.
Latest:
Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic MalignanciesJeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.
Latest:
Future of R/R DLBCLA panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
Latest:
Atrium Health Levine Cancer Institute’s Breast Program Earns NAPBC AccreditationAtrium Health Levine Cancer Institute’s breast cancer program has been granted accredited status by the National Accreditation Program for Breast Centers, a quality program administered by the American College of Surgeons.
Latest:
Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple MyelomaLisa Leypoldt, MD, discusses findings from the phase 2 GMMG-CONCEPT trial in patients with multiple myeloma.
Latest:
Deciding When to Defer Oncology TreatmentOncologists are challenged to make a different determination when a new patient presents with advanced cancer.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRCAdagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.
Latest:
Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer CareDavid Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Dr. Vogl on the Utilization of Modakafusp Alfa in Relapsed/Refractory Multiple MyelomaDan Vogl, MD, MSCE, discusses the utilization of modakafusp alfa in relapsed/refractory multiple myeloma.
Latest:
Dr. Lara on Role of Molecular Differences in Disparities in Uterine Serous CarcinomaOliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.
Latest:
Drs Edelman and Fleisher on Personalizing and Adapting Treatment Approaches in Clinical TrialsMartin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
ACCC Releases Trending Now in Cancer CareThe Association of Community Cancer Centers today released its annual Trending Now in Cancer Care report, including actionable strategies in 8 key areas.
Latest:
Dr Dima on Real-World Responses With Teclistamab in R/R Multiple MyelomaDanai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.
